Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986288

Next Previous
X
Search
Drug Profile

BMS 986288

Alternative Names: Anti-CTLA-4 NF Probody - Bristol Myers Squibb; BMS-986288

Latest Information Update: 21 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytomX Therapeutics
  • Developer Bristol-Myers Squibb
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 31 Aug 2024 Bristol-Myers Squibb completes a phase I/II trial for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Combination-therapy Recurrent, Second-line therapy or greater) in the US, Argentina, Canada, Chile, France, Italy and Spain (Parenteral) (NCT03994601)
  • 05 Apr 2024 Pharmacodynamics data from preclinical studies in Cancer were presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 06 Mar 2024 Bristol Myers Squibb terminates its licence for BMS 986288

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top